Ovid Therapeutics (OVID) Competitors

XBiotech (NASDAQ:XBIT) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations.

Does the media refer more to XBIT or OVID?

In the previous week, XBiotech and XBiotech both had 1 articles in the media. XBiotech's average media sentiment score of 0.59 beat Ovid Therapeutics' score of 0.00 indicating that XBiotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
XBiotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ovid Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is XBIT or OVID more profitable?

XBiotech has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -4,562.23%. XBiotech's return on equity of -21.14% beat Ovid Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XBiotech	N/A	-21.14%	-19.55%
Ovid Therapeutics	-4,562.23%	-34.17%	-25.34%

Do analysts rate XBIT or OVID?

Ovid Therapeutics has a consensus target price of $3.13, indicating a potential upside of 735.56%. Given Ovid Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Ovid Therapeutics is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XBiotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Ovid Therapeutics	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.20

Do insiders and institutionals believe in XBIT or OVID?

55.7% of XBiotech shares are owned by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are owned by institutional investors. 33.1% of XBiotech shares are owned by insiders. Comparatively, 13.1% of Ovid Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Which has preferable valuation & earnings, XBIT or OVID?

Ovid Therapeutics has lower revenue, but higher earnings than XBiotech. XBiotech is trading at a lower price-to-earnings ratio than Ovid Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XBiotech	$4.01M	23.19	-$38.53M	-$1.29	-2.36
Ovid Therapeutics	$570K	46.66	-$26.43M	-$0.35	-1.07

Which has more volatility and risk, XBIT or OVID?

XBiotech has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Comparatively, Ovid Therapeutics has a beta of 0.13, suggesting that its share price is 87% less volatile than the S&P 500.

Summary

Ovid Therapeutics beats XBiotech on 9 of the 16 factors compared between the two stocks.